FDA Approval Alert: The Need-to-Know | Blinatumomab in CD19+ Ph– B-Cell Precursor Acute Lymphoblastic Leukemia

In June 2024, the FDA approved blinatumomab as a treatment for adult and pediatric patients 1 month or older with CD19-positive Philadelphia chromosome–negative B-cell precursor acute lymphoblastic leukemia.

Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
“Promising” Data Support Blinatumomab in CD19+ B-ALL Population
Video
Jun 17, 2024 1:00 PM
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.
FDA Approves Blinatumomab in CD19+ Ph– B-Cell ALL
Article
Jun 14, 2024 9:07 PM
Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.